Themis Medicare Limited (THEMISMED.NS)
INR 128.07
(-0.93%)
INR 128.07
(-0.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.81 Billion INR | 7.74% |
| 2022 | 3.54 Billion INR | -10.21% |
| 2021 | 3.94 Billion INR | 71.07% |
| 2020 | 2.3 Billion INR | 14.43% |
| 2019 | 2.01 Billion INR | 9.71% |
| 2018 | 1.83 Billion INR | -12.29% |
| 2017 | 2.09 Billion INR | -14.77% |
| 2016 | 2.45 Billion INR | 5.59% |
| 2015 | 2.32 Billion INR | 15.31% |
| 2014 | 2.01 Billion INR | 3.49% |
| 2013 | 1.95 Billion INR | 12.43% |
| 2012 | 1.73 Billion INR | 10.06% |
| 2011 | 1.57 Billion INR | -37.01% |
| 2010 | 2.5 Billion INR | 9.6% |
| 2009 | 2.28 Billion INR | 6.44% |
| 2008 | 2.14 Billion INR | -10.09% |
| 2007 | 2.38 Billion INR | 34.35% |
| 2006 | 1.77 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.22 Billion INR | 25.74% |
| 2024 Q2 | 1.17 Billion INR | -4.87% |
| 2023 Q2 | 1.04 Billion INR | 8.42% |
| 2023 Q3 | 825.12 Million INR | -21.25% |
| 2023 Q4 | 978.17 Million INR | 18.55% |
| 2023 FY | 3.81 Billion INR | 7.74% |
| 2023 Q1 | 966.48 Million INR | 20.65% |
| 2022 Q1 | 944.35 Million INR | 18.34% |
| 2022 Q2 | 910.03 Million INR | -3.63% |
| 2022 Q4 | 801.04 Million INR | -9.77% |
| 2022 Q3 | 887.8 Million INR | -2.44% |
| 2022 FY | 3.54 Billion INR | -10.21% |
| 2021 Q4 | 797.97 Million INR | -15.93% |
| 2021 FY | 3.94 Billion INR | 71.07% |
| 2021 Q1 | 1.12 Billion INR | 82.12% |
| 2021 Q2 | 1.07 Billion INR | -4.54% |
| 2021 Q3 | 949.22 Million INR | -11.61% |
| 2020 Q4 | 617.73 Million INR | -5.71% |
| 2020 Q1 | 484.88 Million INR | 5.06% |
| 2020 Q3 | 655.15 Million INR | 19.35% |
| 2020 FY | 2.3 Billion INR | 14.43% |
| 2020 Q2 | 548.92 Million INR | 13.21% |
| 2019 Q3 | 537.77 Million INR | 6.86% |
| 2019 Q1 | 513.33 Million INR | 43.74% |
| 2019 Q4 | 461.54 Million INR | -14.18% |
| 2019 FY | 2.01 Billion INR | 9.71% |
| 2019 Q2 | 503.23 Million INR | -1.97% |
| 2018 Q2 | 494.91 Million INR | -1.91% |
| 2018 FY | 1.83 Billion INR | -12.29% |
| 2018 Q1 | 504.57 Million INR | -3.35% |
| 2018 Q3 | 480.93 Million INR | -2.83% |
| 2018 Q4 | 357.13 Million INR | -25.74% |
| 2017 Q2 | 620.63 Million INR | 15.68% |
| 2017 Q3 | 499.98 Million INR | -19.44% |
| 2017 Q4 | 522.04 Million INR | 4.41% |
| 2017 FY | 2.09 Billion INR | -14.77% |
| 2017 Q1 | 536.5 Million INR | -3.77% |
| 2016 Q1 | 671.21 Million INR | 24.76% |
| 2016 FY | 2.45 Billion INR | 5.59% |
| 2016 Q4 | 557.53 Million INR | -10.98% |
| 2016 Q3 | 626.3 Million INR | 3.87% |
| 2016 Q2 | 602.95 Million INR | -10.17% |
| 2015 Q2 | 638.67 Million INR | 7.32% |
| 2015 Q1 | 595.12 Million INR | 19.76% |
| 2015 FY | 2.32 Billion INR | 15.31% |
| 2015 Q4 | 538 Million INR | -3.27% |
| 2015 Q3 | 556.16 Million INR | -12.92% |
| 2014 Q4 | 496.94 Million INR | 0.21% |
| 2014 Q3 | 495.89 Million INR | 14.36% |
| 2014 Q1 | 592.34 Million INR | 0.0% |
| 2014 FY | 2.01 Billion INR | 3.49% |
| 2014 Q2 | 433.63 Million INR | -26.79% |
| 2013 FY | 1.95 Billion INR | 12.43% |
| 2012 Q3 | 343.56 Million INR | -13.22% |
| 2012 Q1 | 469.95 Million INR | 0.0% |
| 2012 FY | 1.73 Billion INR | 10.06% |
| 2012 Q4 | 525.52 Million INR | 52.96% |
| 2012 Q2 | 395.91 Million INR | -15.75% |
| 2011 FY | 1.57 Billion INR | -37.01% |
| 2010 FY | 2.5 Billion INR | 9.6% |
| 2009 FY | 2.28 Billion INR | 6.44% |
| 2008 FY | 2.14 Billion INR | -10.09% |
| 2007 FY | 2.38 Billion INR | 34.35% |
| 2006 FY | 1.77 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 4.21 Billion INR | 9.37% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -853.56% |
| Caplin Point Laboratories Limited | 16.76 Billion INR | 77.233% |
| FDC Limited | 19.42 Billion INR | 80.351% |
| Gufic Biosciences Limited | 8.06 Billion INR | 52.674% |
| Hikal Limited | 17.84 Billion INR | 78.608% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 70.196% |
| IOL Chemicals and Pharmaceuticals Limited | 21.32 Billion INR | 82.1% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -147.298% |
| Medico Remedies Limited | 1.44 Billion INR | -163.427% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 77.338% |
| Par Drugs and Chemicals Limited | 956.4 Million INR | -299.163% |
| RPG Life Sciences Limited | 5.82 Billion INR | 34.411% |
| Sequent Scientific Limited | 13.69 Billion INR | 72.129% |
| Shilpa Medicare Limited | 11.53 Billion INR | 66.893% |
| Sigachi Industries Limited | 3.98 Billion INR | 4.31% |
| Unichem Laboratories Limited | 16.57 Billion INR | 76.967% |
| Venus Remedies Limited | 5.91 Billion INR | 35.453% |
| Wanbury Limited | 5.75 Billion INR | 33.682% |
| ZIM Laboratories Limited | 3.67 Billion INR | -3.876% |
| Lupin Limited | 196.56 Billion INR | 98.058% |
| Innova Captab Limited | 10.81 Billion INR | 64.694% |
| Ind-Swift Limited | 5.02 Billion INR | 24.023% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 19.361% |
| Aurobindo Pharma Limited | 290.01 Billion INR | 98.684% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 69.173% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 70.532% |
| Mangalam Drugs & Organics Limited | 3.67 Billion INR | -3.922% |
| Morepen Laboratories Limited | 17.01 Billion INR | 77.569% |
| Laurus Labs Limited | 50.01 Billion INR | 92.368% |
| Aarti Drugs Limited | 25.28 Billion INR | 84.902% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 83.28% |
| Alembic Limited | 1.57 Billion INR | -142.41% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 93.754% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 96.768% |
| Vaishali Pharma Limited | 862.79 Million INR | -342.469% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 78.972% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -82.921% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 94.305% |
| Eris Lifesciences Limited | 20.09 Billion INR | 80.999% |
| Windlas Biotech Limited | 6.3 Billion INR | 39.495% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.213% |
| Lincoln Pharmaceuticals Limited | 5.8 Billion INR | 34.241% |
| Orchid Pharma Limited | 8.19 Billion INR | 53.408% |
| Albert David Limited | 3.62 Billion INR | -5.324% |
| Hester Biosciences Limited | 3.04 Billion INR | -25.354% |
| Sakar Healthcare Limited | 1.54 Billion INR | -147.628% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 63.689% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 66.84% |
| Divi's Laboratories Limited | 78.45 Billion INR | 95.134% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.306% |
| Neuland Laboratories Limited | 15.58 Billion INR | 75.506% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.47 Billion INR | 88.927% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 97.993% |
| Wockhardt Limited | 27.89 Billion INR | 86.312% |
| Bal Pharma Limited | 3.39 Billion INR | -12.541% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.632% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 50.436% |
| Alkem Laboratories Limited | 126.67 Billion INR | 96.986% |
| Valiant Laboratories Limited | 1.82 Billion INR | -109.693% |
| Ajanta Pharma Limited | 42.08 Billion INR | 90.929% |
| Bafna Pharmaceuticals Limited | 1.52 Billion INR | -150.391% |
| Aarey Drugs & Pharmaceuticals Limited | 3.95 Billion INR | 3.503% |
| Granules India Limited | 45.06 Billion INR | 91.528% |
| Medicamen Biotech Limited | 1.79 Billion INR | -112.91% |
| Ipca Laboratories Limited | 77.05 Billion INR | 95.046% |
| Brooks Laboratories Limited | 794.86 Million INR | -380.286% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -47.259% |
| Piramal Enterprises Limited | 60.33 Billion INR | 93.673% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.4% |
| NATCO Pharma Limited | 40.02 Billion INR | 90.461% |
| Suven Life Sciences Limited | 116.92 Million INR | -3164.894% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -657.139% |
| Strides Pharma Science Limited | 40.51 Billion INR | 90.576% |
| Indoco Remedies Limited | 18.17 Billion INR | 78.993% |
| Alpa Laboratories Limited | 1.08 Billion INR | -251.08% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -265.899% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -405.34% |